What is 2-AG?
2-AG, short for 2-arachidonoylglycerol, is a lipid signaling molecule made in the body. It is one of the major endocannabinoids, alongside anandamide. Both interact with cannabinoid receptors, but they are different molecules with different metabolic pathways.
Sources checked September 12, 2026 · 4 minute read
What does 2-AG stand for?
The full name is 2-arachidonoylglycerol. It describes a specific lipid, a member of the broad family of fat-related molecules. “Endocannabinoid” means that it is produced within the body and can act at cannabinoid receptors. A receptor is the protein receiving a signal; 2-AG is a molecule that can deliver one.
A 1995 study by Sugiura and colleagues identified 2-AG in rat brain and investigated its interaction with cannabinoid receptors. That finding expanded the picture beyond anandamide: the body had more than one naturally occurring cannabinoid signal.
2-AG vs. anandamide: what is the difference?
The names sometimes appear together because both are endocannabinoids. They are not two abbreviations for the same chemical. Their structures differ, and the enzymes involved in controlling them are not identical.
2-arachidonoylglycerol. A monoacylglycerol studied extensively as a signal between nerve cells. MAGL is an important breakdown enzyme.
Also called AEA, or arachidonoylethanolamide. A fatty acid amide. FAAH is an important enzyme that breaks it down.
Both belong to endocannabinoid biology. Shared receptor targets do not make their timing, location or effects interchangeable.
The enzyme distinction comes from experimental work: a 2002 brain-lipase study supported a role for monoglyceride lipase, also called MGL or MAGL, in ending 2-AG activity. A 1996 study of FAAH showed that this different enzyme breaks down anandamide.
These are useful landmarks, not a complete map of every pathway in every tissue. See our anandamide guide for more on AEA.
What does 2-AG do in the brain?
One well-studied role is retrograde signaling: feedback from a receiving nerve cell toward the cell sending it a message. This can reduce neurotransmitter release at a synapse, the junction where nerve cells communicate.
Open each part of the feedback loop
1. A receiving cell makes a signal
Activity can trigger production of 2-AG. Diacylglycerol lipase alpha, often written DAGLα or DGLα, is a key enzyme in this process at many brain synapses.
2. The signal travels back
2-AG can reach CB1 receptors on the sending side of a synapse and reduce further transmitter release. “Retrograde” describes this direction of communication.
3. Breakdown limits the message
Enzymes including MAGL help inactivate 2-AG. Making a signal and ending it are both parts of controlling communication.
This simplified model draws on the enzyme studies above and 2010 research in mice. It describes a cellular mechanism, not a guaranteed feeling or health outcome.
What do 2-AG studies actually show?
In the 2010 mouse experiment, removing DGLα eliminated the measured endocannabinoid feedback suppression in several tested brain regions. This supported the importance of 2-AG made through that enzyme for the signaling process.
A separate study of postmortem human hippocampus found the production and breakdown machinery arranged in locations consistent with feedback signaling. Human tissue evidence helps connect the cellular model to human biology, but it is not a treatment trial.
Common questions about 2-AG
Is 2-AG the same as THC?
No. 2-AG is an endocannabinoid made in the body. THC is a chemically different cannabinoid associated with the cannabis plant. Interacting with cannabinoid receptors does not make them the same substance.
Is 2-AG a receptor?
No. It is a signaling molecule. CB1 and CB2 are cannabinoid receptors. Keeping the messenger separate from its target makes research easier to follow.
Does more 2-AG always mean better health?
No such conclusion follows from these studies. A biological signal has a context, including where and when it acts. “More” is not enough information to establish a benefit.
Keep learning
Chris Garcia, Owner and CEO
September 12, 2026
How this page is prepared: Plenny uses linked research and other relevant sources for educational explanations, and product details and batch COAs where relevant. General strain, flavor, and effect descriptions are not guarantees.
Commercial transparency: Plenny sells products discussed on this website. Educational pages are not medical or legal advice, and content is not medically reviewed unless a named licensed reviewer is shown.